Your browser doesn't support javascript.
loading
Baseline Carotid Intima-Media Thickness and Stroke Recurrence During Secondary Prevention With Pravastatin.
Wada, Shinichi; Koga, Masatoshi; Minematsu, Kazuo; Toyoda, Kazunori; Suzuki, Rieko; Kagimura, Tatsuo; Nagai, Yoji; Aoki, Shiro; Nezu, Tomohisa; Hosomi, Naohisa; Origasa, Hideki; Ohtsuki, Toshiho; Maruyama, Hirofumi; Yasaka, Masahiro; Kitagawa, Kazuo; Uchiyama, Shinichiro; Matsumoto, Masayasu.
Afiliação
  • Wada S; From the Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan (S.W., M.K., K.M., K.T., R.S.).
  • Koga M; From the Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan (S.W., M.K., K.M., K.T., R.S.).
  • Minematsu K; From the Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan (S.W., M.K., K.M., K.T., R.S.).
  • Toyoda K; From the Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan (S.W., M.K., K.M., K.T., R.S.).
  • Suzuki R; From the Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan (S.W., M.K., K.M., K.T., R.S.).
  • Kagimura T; Foundation for Biomedical Research and Innovation at Kobe, Translational Research Center for Medical Innovation, Japan (T.K.).
  • Nagai Y; Center for Clinical Research, Kobe University Hospital, Japan (Y.N.).
  • Aoki S; Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Japan (S.A., T.N., N.H., T.O., H.M., M.M.).
  • Nezu T; Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Japan (S.A., T.N., N.H., T.O., H.M., M.M.).
  • Hosomi N; Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Japan (S.A., T.N., N.H., T.O., H.M., M.M.).
  • Origasa H; Division of Biostatistics and Clinical Epidemiology, University of Toyama Graduate School of Medicine and Pharmaceutical Science, Japan (H.O.).
  • Ohtsuki T; Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Japan (S.A., T.N., N.H., T.O., H.M., M.M.).
  • Maruyama H; Stroke Center, Kinki University Hospital, Osakasayama, Japan (T.O.).
  • Yasaka M; Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Japan (S.A., T.N., N.H., T.O., H.M., M.M.).
  • Kitagawa K; Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Japan (S.A., T.N., N.H., T.O., H.M., M.M.).
  • Uchiyama S; Department of Cerebrovascular Medicine and Neurology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan (M.Y.).
  • Matsumoto M; Department of Neurology, Tokyo Women's Medical University, Japan (K.K.).
Stroke ; 50(6): 1586-1589, 2019 06.
Article em En | MEDLINE | ID: mdl-31035902
ABSTRACT
Background and Purpose- As a prespecified post hoc analysis of the J-STARS (Japan Statin Treatment Against Recurrent Stroke) Echo Study, the 5-year stroke recurrence rate according to the baseline mean carotid intima-media thickness (IMT) with and without pravastatin treatment was investigated. Methods- Patients were randomly assigned to receive pravastatin 10 mg/day (pravastatin group) or control group (nonstatin treatment; 11) for 5 years. Baseline mean IMT of the common carotid artery was measured by ultrasonography. Cox proportional hazards models were used to investigate whether the stroke (any ischemic stroke, atherothrombotic brain infarction, or lacunar infarction) recurrence rate was different according to tertiles of baseline mean IMT. Results- A total of 793 patients, including 388 in the pravastatin group and 405 in the control group, were investigated. In the control group, Cox proportional hazards models showed that participants in the highest tertile IMT group (≥0.931 mm) had a higher rate of atherothrombotic brain infarction than those in the lowest tertile IMT group (<0.812 mm; [hazard ratio, 9.08; 95% CI, 1.15-71.43]). Patients in the pravastatin group had a lower risk of atherothrombotic brain infarction than those in the control group only in the highest tertile IMT group by the log-rank test ( P value=0.045). Conclusions- Long-term pravastatin administration may prevent the occurrence of atherothrombotic brain infarction in noncardioembolic infarction patients with the highest tertile IMT. Clinical Trial Registration- URL https//www.clinicaltrials.gov . Unique identifier NCT00361530.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pravastatina / Acidente Vascular Cerebral / Infarto Encefálico / Espessura Intima-Media Carotídea Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pravastatina / Acidente Vascular Cerebral / Infarto Encefálico / Espessura Intima-Media Carotídea Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article